Assessment of Stent Strut Coverage and Endothelial Function After Drug-Eluting Stents
NCT ID: NCT01073111
Last Updated: 2018-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2010-04-30
2017-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vessel Wall Response of the Zotarolimus Drug-eluting Stent Implanted in AMI Assessed by Optical Coherence Tomography
NCT00704561
Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting Cobalt-CHromium Stent
NCT02014818
Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction
NCT01347554
COMPARE-II- Vasomotion and Imaging Substudy
NCT01329237
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen
NCT01267734
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
zotarolimus-eluting stents (ENDEAVOR®)
zotarolimus-eluting stent (ENDEAVOR®)
zotarolimus-eluting stent
sirolimus-eluting stents (CYPHER SELECT® PLUS)
sirolimus-eluting stents (CYPHER SELECT® PLUS)
sirolimus-eluting stents
everolimus-eluting stents (PROMUS®)
everolimus-eluting stents (PROMUS®)
everolimus-eluting stents
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
zotarolimus-eluting stent (ENDEAVOR®)
zotarolimus-eluting stent
sirolimus-eluting stents (CYPHER SELECT® PLUS)
sirolimus-eluting stents
everolimus-eluting stents (PROMUS®)
everolimus-eluting stents
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with stable or acute coronary syndrome considered for coronary revascularization
* Reference vessel diameter of 2.5 to 3.5 mm by operator assessment
Exclusion Criteria
* Ostial lesion within 5 mm from ostium
* Different DES in other vessel simultaneously
* Creatinine level 2.5 mg/dL
* Left main stenosis more than 50%.
* vein graft lesion
* Triple vessel disease with stenosis more than 50% in 3 epicardial coronary arteries
* Life expectancy 1 year
* Reference vessel \< 2.5 mm or \> 4.0 mm diameter by visual
* Long lesion that require more than three stents
25 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hyogo Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kenichi Fujii
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hyogo College of Medicine
Nishinomiya, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ASSESS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.